Quantcast

Latest Psoriatic arthritis Stories

2014-07-09 08:28:16

Psoriasis Foundation will drive efforts to cure psoriatic disease, help those affected PORTLAND, Ore., July 9, 2014 /PRNewswire-USNewswire/ -- National Psoriasis Foundation will double the number of researchers studying psoriasis and psoriatic arthritis while also cutting in half the number of people who say these chronic conditions are a problem in their daily lives as part of its new five-year strategic plan and mission to cure psoriatic disease and improve the lives of those affected....

2014-07-07 16:02:23

European League Against Rheumatism Low dosing of infliximab does not appear to alter treatment response or adherence Data presented today at the European League Against Rheumatism Annual Congress (EULAR 2014) showed that a significant number of patients with psoriatic arthritis (PsA) were not receiving doses of the tumour necrosis factor-alpha (TNFα) inhibitor adalimumab necessary to achieve optimal clinical benefit. Further data revealed that, in the case of the TNFα inhibitor...

2014-07-03 08:23:24

- Dermira obtains exclusive rights to develop Cimzia® in psoriasis in the US, Canada and the European Union BRUSSELS and REDWOOD CITY, Calif., July 3, 2014 /PRNewswire/ -- UCB, a global biopharmaceutical leader (Euronext: UCB), and Dermira, Inc., a privately held US-based dermatology company, announced today that they have entered into an exclusive licensing agreement for the development and future commercialization of Cimzia(®) (certolizumab pegol) in dermatology. This collaboration aims...

2014-06-26 23:02:08

Patient advocacy group teams with The Dermatologist to educate healthcare providers on the specifics of psoriasis research and treatment. Malvern, PA (PRWEB) June 26, 2014 The Dermatologist, a leading publication in the field of dermatology, is proud to announce a collaboration with the National Psoriasis Foundation, the world’s leading patient advocacy organization dedicated to the 7.5 million Americans with psoriasis and psoriatic arthritis, to educate dermatologists on the latest...

2014-06-26 08:28:32

NPF Psoriatic Arthritis Project to improve diagnosis, care and treatment for millions PORTLAND, Ore., June 26, 2014 /PRNewswire-USNewswire/ -- Millions of Americans with psoriatic arthritis--a serious disease that causes pain, swelling and stiffness of the joints and tendons, and can result in joint damage if left untreated--struggle to get the health care and treatments they need to manage their condition. National Psoriasis Foundation plans to change that by launching the largest...

2014-06-18 08:28:40

~Expert panel shares tips, encouraging patients to take a 360° approach to managing their disease and to not give up until they're satisfied~

2014-06-11 16:27:22

Phase 3 Program Underway to Further Assess Brodalumab as Potential Treatment for People Living With Psoriatic Arthritis THOUSAND OAKS, Calif. and LONDON, June 11, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced that results from a Phase 2 study evaluating brodalumab in 168 patients with psoriatic arthritis were published in The New England Journal of Medicine (NEJM). These data will also be presented at the 2014 European League Against Rheumatism (EULAR)...

2014-05-13 08:31:25

Consensus Statement Supports Adoption of Psoriasis Resolution by the World Health Organization (WHO) at Upcoming 67th World Health Assembly PORTLAND, Ore., May 13, 2014 /PRNewswire-USNewswire/ -- The International Federation of Psoriasis Associations (IFPA), European Federation of Psoriasis Associations (EUROPSO), National Psoriasis Foundation (NPF) and The Arthritis Society today issued a joint consensus statement to provide a framework addressing the unmet needs faced by the over 125...

2014-05-05 00:21:27

COVA322 is First of Covagen's Bispecific FynomAbs to Enter Clinical Trials ZURICH-SCHLIEREN, Switzerland, May 5, 2014 /PRNewswire/ -- Covagen today announced it has initiated a Phase Ib/IIa study with COVA322, a bispecific TNF/IL-17A inhibitor. COVA322 is Covagen's lead bispecific FynomAb® developed for treatment of patients with rheumatoid arthritis, psoriatic arthritis and other inflammatory diseases. The trial will enroll 39 patients with psoriasis and evaluate safety as well as...

2014-05-01 12:32:22

Patented French maritime pine bark extract shown to significantly reduce the most common signs of psoriasis by reducing inflammation, increasing skin hydration and fighting free radicals HOBOKEN, N.J., May 1, 2014 /PRNewswire/ -- A new peer-reviewed study published in the March issue of the Panminerva Medica found that supplementation with Pycnogenol(®) (pic-noj-en-all), a standardized natural plant extract from French maritime pine tree bark, significantly improves the painful and visible...


Word of the Day
mundungus
  • A stinking tobacco.
  • Offal; waste animal product; organic matter unfit for consumption.
This word comes from the Spanish 'mondongo,' tripe, entrails.